$3.42
3.17% today
Nasdaq, Sep 03, 06:47 pm CET
ISIN
US8051111016
Symbol
SVRA

Savara, Inc. Stock price

$3.31
+0.74 28.79% 1M
+0.99 42.67% 6M
+0.24 7.82% YTD
-0.96 22.48% 1Y
+1.86 128.28% 3Y
+1.91 136.43% 5Y
-30.02 90.07% 10Y
-6,909.19 99.95% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.03 0.91%
ISIN
US8051111016
Symbol
SVRA
Industry

Key metrics

Basic
Market capitalization
$572.1m
Enterprise Value
$455.3m
Net debt
positive
Cash
$146.4m
Shares outstanding
172.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.8
Financial Health
Equity Ratio
80.5%
Return on Equity
-56.0%
ROCE
-78.2%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-117.3m | $-39.0m
EBIT
$-117.4m | $-115.9m
Net Income
$-110.3m | $-90.2m
Free Cash Flow
$-99.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-45.6% | 62.1%
EBIT
-45.5% | -12.5%
Net Income
-47.7% | 6.0%
Free Cash Flow
-38.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
12.2%
Employees
59
Rev per Employee
$0.0
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

Buy
79%
Hold
21%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
67% 67%
-
- Research and Development Expense 84 84
37% 37%
-
-117 -117
46% 46%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -117 -117
46% 46%
-
Net Profit -110 -110
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
one day ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced an increased estimate of autoimmune PAP diagnosed prevalence in the U.S. The updated analysis indicates an ~50% larger autoimmune PAP patient population in the U.S. than the Company's previously estimated claims analysis fr...
Neutral
Business Wire
8 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at two upcoming healthcare conferences. Wells Fargo Securities Healthcare Conference September 3, 2025, 4:30pm ET/1:30pm PT H.C. Wainwright Global Healthcare...
Neutral
Business Wire
14 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled “A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis” will appear in the Au...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today